

**KREBS BIOCHEMICALS & INDUSTRIES LIMITED**

CIN: L24110AP1991PLC103912

Registered Office: Kothapalli Village, Kasimkota Mandal, Ankapalli, Visakhapatnam, Andhra Pradesh - 531 031

Corporate Office: 8-2-577/B, Plot No:34, 3rd Floor, Maas Heights, Road No:8, Banjara Hills, Hyderabad - 500 034

**STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2017**

(Rs. In Lacs)

Sl.No	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2017 (Un Audited)	30.09.2017 (Un Audited)	31.12.2016 (Un Audited)	31.12.2017 (Un Audited)	31.12.2016 (Un Audited)	31.03.2017 (Audited)
	<b>PART - 1</b>						
1	Revenue from Operations						
	a) Net Sales/Income from Operations	1578.50	227.15	1.45	1882.04	8.58	197.02
	b) Other Operating Income	363.12	178.74	39.00	580.86	117.00	156.00
2	Other Income	1.15	-	3.70	5.18	6.58	7.52
3	<b>Total Income (1+2)</b>	<b>1,942.77</b>	<b>405.89</b>	<b>44.15</b>	<b>2,468.08</b>	<b>132.16</b>	<b>360.54</b>
4	<b>Expenses</b>						
	a) Cost of Materials Consumed	963.41	184.47	0.03	1,178.29	0.83	133.99
	b) Changes in Inventories of Finished Goods, Work-In-Progress	(224.60)	(100.01)	1.47	(314.52)	(0.85)	(41.68)
	c) Employee Benefits Expenses	309.92	288.61	141.88	748.93	415.18	562.59
	d) Finance Costs	141.78	124.42	87.35	376.39	207.72	348.85
	e) Depreciation and Amortisation Expenses	101.86	101.85	104.09	305.57	312.28	423.37
	f) Other Manufacturing Expenses	428.72	204.99	91.23	845.04	227.92	176.80
	g) Other Expenses	104.62	87.59	68.99	271.74	206.44	321.32
	<b>Total Expenses (4)</b>	<b>1,825.71</b>	<b>891.92</b>	<b>495.04</b>	<b>3,411.44</b>	<b>1,369.52</b>	<b>1,925.24</b>
5	<b>Profit / (Loss) before exceptional items and tax (3±4)</b>	<b>117.06</b>	<b>(486.03)</b>	<b>(450.89)</b>	<b>(943.36)</b>	<b>(1,237.36)</b>	<b>(1,564.70)</b>
6	<b>Exceptional Items:</b>						
	a) Depletion in Value of Inventory	(72.82)	-	(4.04)	(95.35)	(14.29)	(67.56)
	b) Amounts Written Back	-	-	4.33	-	5.74	31.66
	c) Prior Period Income/(Expenditure)	-	-	(1.00)	3.56	6.46	(4.34)
7	<b>Profit / (Loss) before Tax (5±6)</b>	<b>44.24</b>	<b>(486.03)</b>	<b>(451.60)</b>	<b>(1,035.15)</b>	<b>(1,239.45)</b>	<b>(1,604.94)</b>
8	<b>Tax Expense</b>						
	a) Current Tax	-	-	-	-	-	-
	b) Deferred Tax	-	-	-	-	-	-
9	<b>Profit / (Loss) for the period (7±8)</b>	<b>44.24</b>	<b>(486.03)</b>	<b>(451.60)</b>	<b>(1,035.15)</b>	<b>(1,239.45)</b>	<b>(1,604.94)</b>
10	Other Comprehensive Income	(23.50)	(22.05)	-	(66.75)	-	451.26
11	<b>Total Comprehensive Income for the period(9±10) (Comprising Profit / (Loss) and Other Comprehensive Income for the period)</b>	<b>20.74</b>	<b>(508.08)</b>	<b>(451.60)</b>	<b>(1,101.90)</b>	<b>(1,239.45)</b>	<b>(1,153.68)</b>
12	Paid-up equity share capital (Face value of Rs 10/- each)	1,374.43	1,374.43	1,374.43	1,374.43	1,374.43	1,374.43
13	Other Equity						(1,226.74)
14	<b>Earning Per Share (of Rs.10/- each) (not Annualised):</b>						
	a) Basic	0.15	(3.70)	(3.29)	(8.02)	(9.02)	(8.39)
	b) Diluted	0.15	(3.70)	(3.29)	(8.02)	(9.11)	(8.46)
	<i>See accompanying notes to the Financial results</i>						

1 The above results have been reviewed by the Audit Committee at its meeting held on 13th February,2018 and approved by the Board of Directors of the Company at its meeting held on 13th February,2018. The results are subject to limited review by statutory auditors.

2 The Company is operating in one segment only hence no segment results have been disclosed.

3 Figures for the quarter ended 30th September,2017 have been regrouped to make them comparable with the current quarter figures. However there is no change in the profit for the quarter ended 30th September,2017.

4 Post implementation of Goods and Services Tax ("GST") with effect from 1st July,2017, revenue from operations is disclosed net of GST. Revenue from operations for the earlier periods included excise duty which is now subsumed in the GST. Revenue from operations for the nine months ended 31st December,2017 includes excise duty upto 30th June,2017. Accordingly, revenue from operations for the quarter and nine months ended 31st December,2017 are not comparable with those of the previous periods presented.


5 Changes in Work In Progress includes Job work service under process. When compared to previous quarter Job work service under process is decreased by Rs. 85.13 lacs for the quarter ended 31st December,2017 and increased by Rs. 131.13 lacs for the quarter ended 30th September,2017.

6 The above financial results are prepared in accordance with IND AS notified under the Company (Indian Accounting Standards) Rules, 2015

Place : Hyderabad

Date : 13.02.2018

  
 Avinash Ravi  
 Managing Director  
 DIN: 01616152





## PAVULURI & Co.

CHARTERED ACCOUNTANTS

# 105, 1st Block, 1st Floor, Divya Shakti Complex,  
Ameerpet, Hyderabad - 500 016.  
Ph : 040 - 2373 1837, 4025 8691  
Fax : 040 - 2374 8729  
Email : pavuluriandco@gmail.com  
pavuluriandco@hotmail.com

### Limited Review Report

**Review Report to  
The Board of Directors,  
KREBS BIOCHEMICALS & INDUSTRIES LIMITED**

- a) We have reviewed the accompanying statement of unaudited standalone financial results of **M/s. KREBS BIOCHEMICALS & INDUSTRIES LIMITED** ("the company") for the quarter ended **31st December, 2017** and the year to date from 1<sup>st</sup> April 2017 to 31<sup>st</sup> December 2017 (the "Statement") attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, read with SEBI circular No CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July 2016.
- b) The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim financial reporting (Ind AS 34) specified under section 133 of the Companies Act 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015 and SEBI circular No. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July 2016 is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to express a conclusion on the statement based on our review.
- c) We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information performed by the independent Auditor of Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- d) Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying statement of un-audited financial results for the Quarter ended 31<sup>st</sup> December 2017 prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim financial reporting (Ind AS 34) specified under section 133 of the Companies Act 2013 read with relevant rules issued thereafter and other recognized accounting practices and policies has disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, read with circular No. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For PAVULURI & Co.**  
**Chartered Accountants**  
**Firm Regn. No: 012194S**

*N. Rajesh*  
**(CA. N. RAJESH)**  
**PARTNER**  
**M.No: 223169**



Place: Hyderabad  
Date: 13.02.2018